⏳ Fetching live dividend data...
Home › Calculator › PSCBF Dividend Calculator 2026
Pascal Biosciences Inc. · OTC
Price: $0.11 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in PSCBF → $67436916049.35M in 10 years · $5,326,770,620,012,143.00/month
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PSCBF position with:
Real after-tax yield depends on where you live and how you hold PSCBF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1818.18% | 1815.38% | $181,818 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1545.45% | 1542.65% | $154,545 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1454.54% | 1451.74% | $145,454 / yr |
| 🇬🇧 UK ISA | 0% | 1818.18% | 1815.38% | $181,818 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1659.09% | 1656.29% | $165,909 / yr |
| 🇨🇦 TFSA | 0% | 1818.18% | 1815.38% | $181,818 / yr |
| 🇨🇦 CA Taxable | 25% | 1363.63% | 1360.84% | $136,364 / yr |
| 🇦🇺 Super (pension) | 15% | 1545.45% | 1542.65% | $154,545 / yr |
| 🇦🇺 AU Taxable | 30% | 1272.73% | 1269.93% | $127,273 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1338.64% | 1335.84% | $133,864 / yr |
| 🇫🇷 FR Taxable | 30% | 1272.73% | 1269.93% | $127,273 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
PSCBF pays quarterly — 4 times per year. Next ex-div: TBD.
How PSCBF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PSCBF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PSCBF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Pascal Biosciences Inc. (PSCBF) is currently trading at $0.11, 45% below its 52-week high. The current dividend yield is 1818.18% based on an annual payout of $2.00 per share.
Pascal Biosciences Inc. (PSCBF) is a healthcare stock currently trading at $0.11 with a dividend yield of 1818.18%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →